Literature DB >> 19405919

Risk factors for neurological complications in complete hemolytic uremic syndrome caused by Escherichia coli O157.

Takehisa Yamamoto1, Kenichi Satomura, Shintaro Okada, Keiichi Ozono.   

Abstract

BACKGROUND: The aim of the present study was to investigate the predictive parameters for encephalopathy in complete hemolytic uremic syndrome (HUS) in a large outbreak of O157: H7 infection in 1996.
METHODS: A total of 182 inpatients, 71 of whom had complete HUS, including 12 patients with neurological complications, and 46 colitis patients were studied. Presenting signs and symptoms (n = 115) and laboratory data (n = 69) were analyzed using monovariate and multivariate analysis.
RESULTS: After adjusting for age and gender, logistic regression showed that presenting symptoms such as bloody diarrhea (odds ratio [OR] = 7.39), proteinuria (OR = 6.16), hematuria (OR = 8.31), oliguria (OR = 17.4) and a pale face (OR = 10.7) were useful for predicting complete HUS. Also, increased white blood cell counts >12,000 microL/mL (OR = 10.0) and C-reactive protein >1.5 mg/dL (OR = 7.39) at the onset of infection, were useful as predictive laboratory parameters. To predict neurological complications in complete HUS patients, the average daily increase of lactate dehydrase >1200 IU/L per day (OR = 26.3) and creatinine >0.5 mg/dL per day (OR = 12) were found to be useful on multivariate logistic regression.
CONCLUSION: There are useful predictive clinical factors for neurological complications in complete HUS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19405919     DOI: 10.1111/j.1442-200X.2008.02690.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  5 in total

1.  Clinical characteristics and long-term outcome of diarrhea-associated hemolytic uremic syndrome: a single center experience.

Authors:  Takeshi Ninchoji; Kandai Nozu; Keita Nakanishi; Tomoko Horinouchi; Junya Fujimura; Tomohiko Yamamura; Shogo Minamikawa; Shingo Ishimori; Koichi Nakanishi; Norishige Yoshikawa; Ichiro Morioka; Hiroshi Kaito; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2017-01-10       Impact factor: 2.801

2.  Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children.

Authors:  Ryan S McKee; David Schnadower; Phillip I Tarr; Jianling Xie; Yaron Finkelstein; Neil Desai; Roni D Lane; Kelly R Bergmann; Ron L Kaplan; Selena Hariharan; Andrea T Cruz; Daniel M Cohen; Andrew Dixon; Sriram Ramgopal; Annie Rominger; Elizabeth C Powell; Jennifer Kilgar; Kenneth A Michelson; Darcy Beer; Martin Bitzan; Christopher M Pruitt; Kenneth Yen; Garth D Meckler; Amy C Plint; Stuart Bradin; Thomas J Abramo; Serge Gouin; April J Kam; Abigail Schuh; Fran Balamuth; Tracy E Hunley; John T Kanegaye; Nicholas E Jones; Usha Avva; Robert Porter; Daniel M Fein; Jeffrey P Louie; Stephen B Freedman
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

3.  Protection of human podocytes from shiga toxin 2-induced phosphorylation of mitogen-activated protein kinases and apoptosis by human serum amyloid P component.

Authors:  Anne K Dettmar; Elisabeth Binder; Friederike R Greiner; Max C Liebau; Christine E Kurschat; Therese C Jungraithmayr; Moin A Saleem; Claus-Peter Schmitt; Elisabeth Feifel; Dorothea Orth-Höller; Markus J Kemper; Mark Pepys; Reinhard Würzner; Jun Oh
Journal:  Infect Immun       Date:  2014-02-24       Impact factor: 3.441

4.  Frequency of neurological involvement in patients with/without diarrhea hemolytic uremic syndrome: A Systematic review and meta-analysis.

Authors:  Azita Tavasoli; Nazanin Zafaranloo; Rozita Hoseini; Hasan Otukesh; Shahrbanoo Nakhaiee
Journal:  Med J Islam Repub Iran       Date:  2021-07-17

5.  Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS).

Authors:  Sebastian Loos; Jun Oh; Laura van de Loo; Markus J Kemper; Martin Blohm; Raphael Schild
Journal:  Pediatr Nephrol       Date:  2021-05-27       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.